| Patient | John Locke |
|---|---|
| Date of birth | 1966-09-08 |
| Identifiers | MRN HR-EN001-SYN; SSN (made up) 000-01-8305 |
| Document date | 2026-09-17 |
| Author | Prudence Hartwell-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Preventive health visit at 60. [S]
Mr. Locke returns for his preventive visit, having turned 60 last week. He completed the health risk questionnaire beforehand. His asthma has been steady in the three months since tiotropium was added: he uses one or two extra inhalations of budesonide-formoterol a week, sleeps through the night, and has had no flare. The dose counters show no missed maintenance doses. He finished pulmonary rehabilitation in the spring and keeps up the walking program five days a week. The open fires in his rooms have stayed out of use, and the HEPA air cleaner runs in his study and bedroom. He spent four days in the city last month, checked the air quality index each morning, and needed his reliever twice. He has had no fever, weight loss, night sweats, or blood in his sputum. He had a normal colonoscopy eight years ago. [S]
| Element | Detail |
|---|---|
| Visit | Preventive health visit, age 60 |
| Active conditions | Asthma with persistent airflow limitation on budesonide-formoterol maintenance and reliever with add-on tiotropium; exposure to air pollution |
| Medicines | Budesonide-formoterol 160/4.5 mcg two inhalations twice daily plus as needed; tiotropium 2.5 mcg two inhalations daily |
| Screening history | Normal colonoscopy eight years ago; HIV, hepatitis B, and hepatitis C tests negative in his fifties |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, better than for many years |
| Psychosocial | Lives with long-standing friends; busy with writing and his board work; no financial worries |
| Behavioral | Never smoker; wine a few evenings a week (AUDIT-C 2); walks 30 to 40 minutes five days a week; plain diet with fruit and vegetables most days |
| Environmental | No open fires in his rooms; HEPA air cleaner in study and bedroom; checks the air quality index before city trips |
| Activities of daily living | Independent |
| Home safety | Smoke and carbon monoxide alarms fitted; no firearms |
| Sexual health | Not sexually active; no risk factors for sexually transmitted infection |
| Hearing and vision | No hearing difficulty; reading glasses; eye examination last year |
| Sleep | Sleeps through the night; no snoring reported |
| Pain | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight 63.0 kg, up 1 kg since spring; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No hoarseness, sore mouth, or thrush on inhaled corticosteroid; no nasal blockage |
| Cardiovascular | Negative | No chest pain, palpitations, ankle swelling, or breathlessness lying flat |
| Respiratory | Positive | Mild breathlessness on hills; occasional cough after city days; no wheeze at rest; no hemoptysis |
| Gastrointestinal | Negative | No heartburn, bleeding, or change in bowel habit |
| Genitourinary | Negative | No urinary hesitancy or retention on tiotropium; no nocturia |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash or easy bruising |
| Neurological | Negative | No headache, numbness, or weakness |
| Psychiatric | Negative | Mood good; PHQ-2 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry | Two puffs every 4 hours as needed | Respiratory tract route | 2026-03-12 to 2026-03-26 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | Two inhalations twice daily plus one as needed; no more than 12 a day | Respiratory tract route | 2026-03-26 | active | S |
| Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5) | Two inhalations once a day | Respiratory tract route | 2026-06-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-17 | Body height | 178 | cm | S |
| 2026-09-17 | Body weight | 63 | kg | S |
| 2026-09-17 | Body mass index (BMI) [Ratio] | 19.9 | kg/m2 | S |
| 2026-09-17 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-09-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-17 | Heart rate | 74 | /min | S |
| 2026-09-17 | Respiratory rate | 16 | /min | S |
| 2026-09-17 | Body temperature | 36.6 | Cel | S |
| 2026-09-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-17 | Cholesterol [Mass/volume] in Serum or Plasma | 182 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-09-17 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 64 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-17 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 101 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-09-17 | Triglyceride [Mass/volume] in Serum or Plasma | 85 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 2026-09-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Thin, well; BMI 19.9 |
| Mouth | No oral candidiasis |
| Cardiovascular | Regular rhythm; no murmur; no edema; blood pressure 120/74 mmHg |
| Respiratory | Good air entry; faint end-expiratory wheeze on forced expiration only; oxygen saturation 97 percent |
| Abdomen | Soft, non-tender; no masses |
| Skin | No bruising or thinning |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluation | resolved | confirmed | R05.3 | S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit. |
| Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at home | active | confirmed | Z77.110 | S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted. |
| Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPD | active | confirmed | J45.40 | S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R). |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, this season | Completed today | Given today |
| COVID-19 vaccine, this season | Completed today | Given today |
| RSV vaccine | Completed today | Single dose given today; recommended at 60 to 74 with chronic lung disease |
| Recombinant zoster vaccine | Due | Recommended from 50; he preferred not to have a fourth injection today and will have dose 1 at his next visit |
| Pneumococcal conjugate vaccine | Up to date | PCV20 given six months ago |
| Tetanus booster | Up to date | Tdap five years ago |
| Colorectal cancer screening | Up to date | Normal colonoscopy eight years ago; next due in two years |
| Depression screening | Completed today | PHQ-2 0 |
| Lipid screening and cardiovascular risk | Completed today | Total cholesterol 182 mg/dL, HDL 64 mg/dL, LDL 101 mg/dL, triglycerides 85 mg/dL; blood pressure 120/74 mmHg; never smoker; no diabetes; estimated 10-year risk below 7.5 percent, so no statin |
| Diabetes screening | Not indicated | BMI 19.9 with no other risk factors |
| HIV, hepatitis B, and hepatitis C screening | Up to date | One-time tests negative in his fifties |
| Alcohol misuse screening | Completed today | AUDIT-C 2 |
| Prostate cancer screening | Declined | Shared decision about PSA screening at 55 to 69 discussed; he chose not to be screened this year |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never smoker; CT this spring showed no nodules |
| Hearing and vision | Up to date | No concerns; eye examination last year |
Immunizations given today: Influenza vaccine, 2026-2027 season; COVID-19 mRNA vaccine, this season's formula; Respiratory syncytial virus vaccine, single dose [S]
Guideline basis: Global Strategy for Asthma Management and Prevention, 2025 update (2025); Adult Immunization Schedule by Age (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Colorectal Cancer: Screening (2021); Depression and Suicide Risk in Adults: Screening (2023); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022); Prostate Cancer: Screening (2018); Lung Cancer: Screening (2021)
Follow-up: Asthma review next month as booked; zoster vaccine dose 1 then. Next scheduled visit 2026-10-22: asthma review two weeks after a cold with a yellow-zone flare. [S]
Voluntary advance care planning discussion of about 17 minutes, with his consent. He has not written a directive before. He names a long-standing friend in the household where he lives as his health care agent and took the state form to complete. He would want full treatment for any illness he might recover from, including a period on a ventilator for a severe asthma attack, and would not want his life prolonged by machines if he could not recover awareness. He asked that his health information be shared with his care team and his agent. [S]